WO2000014263A2 - Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them - Google Patents
Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them Download PDFInfo
- Publication number
- WO2000014263A2 WO2000014263A2 PCT/US1999/020375 US9920375W WO0014263A2 WO 2000014263 A2 WO2000014263 A2 WO 2000014263A2 US 9920375 W US9920375 W US 9920375W WO 0014263 A2 WO0014263 A2 WO 0014263A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- hav
- nucleic acid
- cell
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Definitions
- the present invention generally relates to the fields of virology, cell biology, and molecular biology. More particularly, it is directed to methods and compositions involving recombinant hepatitis A virus (HAV) expressing heterologous nucleic acid sequences and a forced selection method to identify viral variants, including HAV variants, that may contain characteristics beneficial for a vaccine.
- HAV hepatitis A virus
- Such viruses have diagnostic uses as well as therapeutic uses as HAV vaccine seed virus and vehicles for gene therapy, especially with respect to liver-specific diseases and conditions.
- HAV Hepatitis A virus
- HM175 The genome of wild-type Hepatitis A virus (HAV) strain HM175 has been characterized as containing 7,478 nucleotides and encoding a polypeptide of 2,227 amino acid residues. (Cohen et al, 1987).
- a cell culture-adapted (CC) variant of strain HM175 has been cloned as a cDNA in a plasmid expression vector (Cohen et al, 1989).
- the resultant RNA was infectious when transfected into cultured primary AGMK cells, and the virus exhibited similar growth and attenuation characteristics as the parent virus. (Cohen et al, 1989, 1987).
- HAV variants that are presently used for the production of inactivated HAV vaccines have been derived empirically by passage of the virus in relevant cell cultures. These viruses contain a number of mutations that enhance the growth of the virus in cell culture (compared with wild-type HAV). Some of these mutations have been studied in detail, as in the case of the HM175 strain used for production of vaccine by SmithKline Beecham. However, the repertoire of mutations which is achievable by this empiric approach appears to be limited by cytopathic effects induced by more successfully replicating HAV variants. Thus, available cell culture-adapted strains of HAV remain severely limited in their ability to replicate and produce antigen in suitable cell lines in comparison with other viruses, such as poliovirus, a virus belonging to the same virus family as HAV (family Picornaviridae).
- viruses such as poliovirus, a virus belonging to the same virus family as HAV (family Picornaviridae).
- a recombinant HAV containing non-HAV sequences in a polyprotein region has not been previously described.
- Heterologous sequences could be incorporated into the HAV genome for diagnostic and therapeutic uses, including gene therapy. Therefore, it is the object of the present invention to provide methods and compositions related to recombinant HAV and variants thereof for therapeutic and diagnostic purposes. It is another object of the present invention to provide a general selection method for the identification of viral vaccine candidates.
- the present invention provides a recombinant hepatitis A virus comprising a heterologous nucleic acid sequence.
- the invention further describes several methods for creating and screening various versions of the recombinant hepatitis A virus for use as a prophylactic and therapeutic agent against diseases.
- the nucleic acid sequence in the recombinant hepatitis A virus comprising a heterologous nucleic acid sequence, is comprised within a polyprotein region.
- the recombinant hepatitis A virus comprising a heterologous nucleic acid sequence is an attenuated virus.
- the heterologous nucleic acid sequence of the recombinant hepatitis A virus is located at the 2A/2B junction.
- a gly-gly hinge flanks the heterologous nucleic acid sequence at the 2A/2B junction.
- the heterologous nucleic acid sequence comprises a nucleic acid sequence encoding a selectable marker.
- the selectable marker is a positive selectable marker.
- the positive selectable marker of the recombinant hepatitis A virus is a drug resistance marker.
- the positive selectable marker is a phleomycin resistance gene.
- the heterologous nucleic acid sequence of the recombinant hepatitis virus comprises a nucleic acid sequence for treating a disease or condition.
- the disease or condition is liver-specific.
- the invention also contemplates a method for producing a recombinant hepatitis A virus containing a heterologous nucleic acid sequence comprising: (a) obtaining a vector containing an infectious cDNA copy of the HAV genome; (b) cleaving the HAV genome in a polyprotein region; and (c) inserting a nucleic acid sequence comprising a heterologous nucleic acid sequence into the region.
- the polyprotein region comprises the 2A and 2B coding region.
- the method further comprises incubating the vector with the insertion under conditions to permit transcription. In a further aspect, the method further comprises transfecting the transcribed products into a permissive cell.
- the heterologous nucleic acid sequence is inserted in frame.
- the heterologous nucleic acid sequence further comprises a hepatitis A virus 3C proteinase cleavage site.
- the heterologous nucleic acid sequence further comprises a gly-gly hinge in a flanking cleavage site.
- the heterologous nucleic acid region comprises a selectable marker.
- the step of transfecting the transcribed product containing the heterologous nucleic acid sequence in the coding region into an HAV permissive cell is also contemplated.
- the invention also describes a method for screening for a hepatitis A virus variant that comprises: (a) obtaining a recombinant hepatitis A virus comprising a selectable marker conferring resistance to a selectable agent; (b) infecting a HAV permissive cell with the recombinant HAV; and (c) exposing the infected cell to the selectable agent.
- the selectable marker is located in a polyprotein region.
- the method can further comprise the step of iterating the exposure at a higher concentration level of the selectable agent.
- the method further comprises assaying the recombinant HAV for enhanced replication.
- the assay for enhanced replication comprises comparing replication foci of the cell infected with the recombinant HAV and exposed to the selectable agent with either (i) a cell infected with the recombinant HAV but not exposed to the selectable agent or (ii) a cell infected with a vector containing an infectious cDNA copy of the
- HAV genome and not the selectable marker but exposed to the selectable agent are not the selectable marker but exposed to the selectable agent.
- the method further comprises assaying the recombinant HAV for increased viral antigen production.
- the assay for increased viral antigen production comprises comparing viral antigen production of the cell infected with the recombinant HAV and exposed to the selectable agent with either (i) a cell infected with the recombinant HAV but not exposed to the selectable agent or (ii) a cell infected with a vector containing an infectious cDNA copy of the HAV genome and not the selectable marker but exposed to the selectable agent.
- the viral antigen is derived from HAV.
- the method further comprises identifying at least one mutation in a candidate variant as compared to the recombinant virus.
- the invention also describes the identification of a hepatitis A virus variant by a method of screening which comprises: (a) obtaining a vector encoding a recombinant hepatitis A virus comprising a selectable marker conferring resistance to a selectable agent; (b) incubating the vector under conditions to permit transcription; (c) transfecting a HAV permissive cell with the transcribed product; and (d) exposing the infected cell to the selectable agent.
- the hepatitis A virus variant is identified by a method of screening further comprising iterating the exposure at a higher concentration level of the selectable agent.
- the hepatitis A virus variant is identified by a method of screening further comprising assaying the recombinant HAV for enhanced replication.
- the variant is identified by a method of screening further comprising assaying the recombinant HAV for increased viral antigen production.
- the variant contains at least one nucleic acid sequence mutation compared to the recombinant virus.
- the nucleic acid sequence mutation is identified in the hepatitis A virus variant.
- the invention also provides a method for producing a hepatitis A virus vaccine seed virus comprising: (a) obtaining a recombinant hepatitis A virus variant comprising a selectable marker; (b) identifying at least one nucleic acid sequence mutation in the recombinant HAV variant; (c) obtaining a vector comprising an infectious cDNA copy of the virus; (d) introducing the nucleic acid sequence mutation of the recombinant HAV variant into the vector; (e) incubating the mutated vector under conditions to permit transcription; (f) infecting an HAV permissive cell with the transcribed product; and (g) incubating the infected cell under conditions to permit viral replication.
- the selectable marker is located in a polyprotein region.
- the permissive cell is an MRC-5 cell.
- the permissive cell is a BSC-1 cell.
- the permissive cell is a FRhK-4 cell.
- the invention further describes a method where a hepatitis A virus-based vaccine seed virus is produced.
- the method comprises the following: (a) obtaining a recombinant hepatitis A virus variant comprising a selectable marker; (b) identifying at least one nucleic acid sequence mutation in the recombinant HAV variant; (c) obtaining a vector containing an infectious cD A copy of the HAV genome; (d) introducing the nucleic acid sequence mutation of the recombinant HAV variant into the vector; (e) incubating the mutated vector under conditions to permit transcription; (f) infecting an HAV permissive cell with the transcribed product; and (g) incubating the infected cell under conditions to permit viral replication.
- the selectable marker is located in a polyprotein region.
- the hepatitis A virus variant used to produce the seed virus further comprises a heterologous nucleic acid sequence.
- the hepatitis A virus variant used to produce the seed virus variant has enhanced replication.
- the hepatitis A virus vaccine seed virus used to produce the seed virus variant has increased viral antigen production.
- the heterologous nucleic acid sequence comprises a foreign antigen.
- the foreign antigen elicits an immune response.
- the foreign antigen is derived from the hepatitis C virus.
- the foreign antigen is derived from the hepatitis B virus.
- the instant invention also discloses a method for producing a recombinant virus comprising: (a) obtaining a vector comprising a viral genome, wherein said vector comprises a heterologus nucleic acid sequence; (b) incubating the vector under conditions to permit transcription; (c) transfecting a permissive cell with the transcribed product; and (d) incubating the cell under conditions to permit viral replication.
- the heterologus nucleic acid sequence is located in a polyprotein region.
- the viral genome is derived from a positive-strand RNA virus.
- the positive strand RNA virus is a hepatitis C virus.
- the heterologous nucleic acid sequence encodes a selectable marker.
- the invention also describes a method for producing a viral variant comprising: (a) obtaining a vector comprising a viral genome, wherein said vector comprises a selectable marker conferring resistance to a selectable agent; (b) incubating the vector under conditions to permit transcription; (c) transfecting a permissive cell with the transcribed product; and (d) exposing the infected cell to the selectable agent.
- the selectable marker is located in a polyprotein region. This method may further comprise iterating the exposure at a higher concentration level of the selectable agent. In one aspect this method may further comprise the step of identifying at least one mutation in a candidate variant as compared to the parent virus. In another aspect the nucleic acid sequence mutation is identified.
- the method further comprises assaying the virus for enhanced replication.
- the assaying for enhanced replication can comprise comparing replication foci of the cell transfected with the vector and exposed to the selectable agent with either (i) a cell transfected with the vector but not exposed to the selectable agent or (ii) a cell transfected with a vector capable of producing a virus in a permissive cell, wherein the vector comprises nucleic acid sequences of the virus and exposed to the selectable agent.
- the method further comprising assaying the virus for increased viral antigen production.
- the assaying for increased viral antigen production comprises comparing viral antigen production of the cell transfected with the vector and exposed to the selectable agent with either (i) a cell transfected with the vector but not exposed to the selectable agent or (ii) a cell transfected with a vector capable of producing a virus in a permissive cell, wherein the vector comprises nucleic acid sequences of the virus and exposed to the selectable agent.
- the invention further contemplates a method for producing a viral vaccine seed virus comprising: (a) obtaining a viral variant comprising a selectable marker; (b) identifying at least one nucleic acid sequence mutation in the viral variant; (c) obtaining a vector comprising an infectious cDNA copy of a viral genome used to create the viral variant; (d) introducing the nucleic acid sequence mutation of the viral variant into the vector; (e) incubating the vector under conditions to permit transcription; (f) transfecting a permissive cell with the transcribed product; and (g) incubating the cell under conditions to permit viral replication.
- the viral variant is derived from hepatitis C virus.
- the viral variant is derived from hepatitis B virus.
- FIG. 1 The genetic organization of 18f2AZeo2B (clone #6), a recombinant
- HAV variant in which the zeo gene has been inserted in frame (with flanking 3C cleavage sites) between the 2A and 2B coding regions of the HAV genome.
- FIG. 2 HAV containing the zeo gene at the 2A/2B junction (2AZeo2B) was used to infect BSC-1 cells cultured in increasing concentrations of Zeocin. Replication characteristics of virus harvests taken at each zeocin concentration were evaluated by radioimmunofocus assays in BSC-1 cells.
- As a control BSC-1 cells were infected with the parent virus HM175/18f and incubated under the same conditions. BSC-1 cells infected with HM175/18f incubated in 500 ⁇ g/ml if zeocin were not viable and virus was not recovered.
- the present invention provides compositions of recombinant HAV, recombinant variants, including HAV variants, and vaccine seed virus, including HAV-based vaccine seed virus, as well as methods of making them and using in screening assays.
- Hepatitis A virus is one of five etiologic agents that cause acute viral hepatitis in humans. It is responsible for approximately 30 percent of all reported cases of this disease in the United States, which translates to more than 100,000 cases each year. The virus is quite contagious, being spread primarily by the fecal-oral route. Outbreaks and large-point source epidemics have been observed. While vaccines against HAV exist, the production of inactivated hepatitis A virus (HAV) vaccine is limited by the slow and inefficient growth of this virus in cultured cells.
- HAV is in the Picornaviridae family, which comprises several human pathogens such as poliovirus and rhinovirus.
- HAV is a non-enveloped, positive-stranded RNA virus, which has at least three genotypes, but only a single serotype.
- the present invention takes advantage of two discoveries. The first is the realization that HAV could accommodate a heterologous nucleic acid sequence in a polyprotein region. A heterologous nucleic acid sequence correctly positioned within the genome could behave in such a manner as to have a minimal effect on replication of the virus. Therefore, it is an object of the present invention to produce a recombinant HAV.
- the second discovery involved the use of a forced selection system to identify viral variants that had altered characteristics, some of which could useful for a viral vaccine.
- HAV RNA virus
- HAV is difficult to manipulate using recombinant technology. Consequently, others have cloned the HAV genome as a cDNA that is contained within an expression vector.
- This vector can be transcribed in vitro using standard techniques and the transcribed RNA products can then be transfected into permissible cells, which produce infectious virus.
- these cDNA clones do not encode HAV genomic sequences that contain a heterologous nucleic acid sequence.
- the HAV genome would be genetically stable with a heterologous sequence and, if it could, where the location in the genome of such a sequence could be tolerated.
- heterologous nucleic acid sequences include any nucleic acid sequence encoding either non-HAV sequence or HAV sequence located in a position not normally found. While the recombinant HAV of the present invention can comprise any heterologous nucleic acid sequence, specific embodiments are directed at particular types of heterologous sequences.
- a recombinant HAV contains a selectable marker.
- a selectable marker is generally a gene that encodes for a polypeptide that confers a phenotype onto a cell that expresses it. More specifically, under a particular set of conditions, a selectable gene allows for a cell expressing it to be discriminated from a cell that does not express it. The particular set of conditions frequently includes the presence of a selectable agent, which is the compound that creates the selection.
- a drug resistance marker allows for a cell expressing it to survive under conditions in which that particular drug, the selectable agent, is present. Such a drug resistance marker operates as a positive selectable marker because cells that contain the gene are selected for, as opposed to selected against.
- a similar cell that does not contain the marker may not survive under those same conditions.
- selectable markers for use in mammalian cells including drug resistance markers such as the phleomycin resistance gene (zeo), the hygromycin resistance gene, and the neo gene.
- a recombinant HAV or HAV variant contains a foreign antigen, which is a non-HAV encoded substance that is specifically recognized by an antibody or a T-cell receptor.
- An immunogen is a substance that induces an immune response, and as used herein, the terms "antigen” and “immunogen” are used interchangeably.
- the foreign antigen contemplated by the present invention include all or parts of viral polypeptides, other microbial polypeptides, tumor-specific antigens, or any other nucleic acid-, polypeptide-, or peptide-based epitope, against which an immune response is desired.
- liver-specific gene therapy could be employed against a number of diseases or conditions such as liver abscess, liver cancer, cirrhosis, all forms of hepatitis, biliary atresia, cocidiodomycosis, hemochromatosis, Reye's syndrome, sclerosing cholangitis, and Wilson's disease.
- sequences would include, for example, genes encoding for immunosuppressants for use in transplantations, tumor suppressor genes that could be used for cancer therapy, vascular genes for use in cancer therapy, genes involved in therapy for hemophilia A and B, and hypercholesterolemia.
- HAV hepatitis C virus
- the present invention is also directed at HAV variants and methods of producing and screening for such variants.
- variant is used herein to refer to a virus whose genome has been altered. In some cases, a variant is identified by a phenotypic change compared to a parent virus. However, the present invention is not limited to such variants, as it also includes variants with known nucleic acid mutations that are specifically generated or randomly generated.
- variants with enhanced replication are described, while in other embodiments, variants with increased viral antigen production are disclosed. It is contemplated that variants with other phenotypic characteristics could be created according to the claimed invention. For example, variants that have an altered host specificity or that exhibited slower growth could be produced and identified.
- the methods for screening for variants is not limited to variants with enhanced replication or increased viral replication.
- Attenuated viruses are contemplated to be within the scope of the viral variants and viral vaccines describe herein.
- An attenuated virus is generally one in which continuous passage of the virus in a cell, either in cell culture or in an organism, alters a property or properties of that virus such that it exhibits an altered phenotype with respect to the virus before it was continuously passaged.
- the screening method employs a forced selection technique that is devised to generate variants.
- a selectable agent is exposed to a cell infected with a recombinant virus, such as a recombinant HAV, containing a selectable marker.
- a recombinant virus such as a recombinant HAV
- Increasing concentrations of the selectable agent are then exposed to the cell as the media is iteratively changed.
- selection methods are understood by a skilled artisan.
- the techniques described above equally apply to analysis of variants. PCR may be particularly useful in characterizing variants on a genetic level. (Goswami, 1997, incorporated by reference).
- enhanced replication is intended to be a relative term pertaining to a virus clone's ability to replicate when compared to a similar virus, such as the parent virus that is not recombinant, or the recombinant virus in the absence of selection. This comparison can be done by assaying replication foci size between a cell infected with recombinant HAV but not exposed to the selectable agent or to a cell infected with the same HAV strain that is not recombinant (parent virus) and exposed to the selectable agent. An evaluation of foci size could be undertaken by anyone of skill in the art of virology.
- Increased viral antigen production refers to the relative amount of a viral antigen that is produced compared to a similar virus, such as the parent virus that is not recombinant, or the recombinant virus in the absence of selection.
- An antigen is previously described herein.
- a candidate antigen from HAV is VP3, as described in Pinto, 1998 and Bosch, 1998, each of which is incorporated by reference.
- the present invention also covers HAV vaccine seed virus and methods of producing such virus using recombinant HAV variants with enhanced replication.
- a vaccine is a pathogenic agent that can be administered prophylactically to induce immunity in an organism.
- a vaccine seed virus is used to produce commercially the vaccine on a large scale.
- the present invention utilizes HAV variants containing a selectable marker gene that is ultimately used to create an HAV vaccine because it allows for the selection and identification of variants with altered properties, some of which could be useful in producing a vaccine.
- foreign viral antigens can placed within an HAV variant that has enhanced replication or within a recombinant HAV prior to forced selection to create a HAV-based vaccine that mostly contained HAV sequence but also included a foreign antigen.
- a foreign antigen for example, insertion of hepatitis C or hepatitis B virus proteins that elicit a protective immune response, at the HAV 2A/2B junction would result in liver specific production and induction of a protective immune response.
- This type of vaccine would not be possible in the current setting as a killed formalin inactivated vaccine is used, however, in the advent of the development of a live attenuated this approach of a multivalent chimeric HAV vaccine is possible.
- a hepatitis viral variant could be created and used to produce a HVC live vaccine.
- Recombinant hepatitis A virus (HAV), recombinant HAV variants, and HAV vaccine seed virus of the present invention comprise an HAV virus that contains a heterologous nucleic acid sequence.
- HAV is an RNA virus
- the genome can be manipulated as a cDNA, which can then be subsequently transcribed into RNA that can be transfected into a host cell. These manipulations facilitate application of recombinant technology in creating novel HAV genomes.
- the use of other viral genomes, particularly of positive strand RNA viruses is also envisioned.
- the present invention concerns nucleic acid sequences comprising non-HAV nucleic acid sequences or HAV sequences located at a different position than normally found that are capable of expressing a protein, polypeptide, or peptide derived from these sequences. It also involves nucleic acid sequences, both RNA and DNA, that encode parts and/or all of the HAV genome, some of which may be capable of expressing a protein, polypeptide, or peptide derived from the HAV genome.
- a “nucleic acid sequence” means an RNA or DNA molecule of any length.
- polynucleotide refers to a nucleic acid molecule, RNA or DNA, that is at least 100 nucleotides in length.
- Heterologous sequence is used to refer to a sequence not normally found in a particular context, either because it is derived from a different source, or because it is located in a different place. With HAV-based recombinant viruses, variants and vaccines, non-HAV sequences are understood to be encompassed by the term “heterologous.”
- DNA segment refers to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a heterologous sequence refers to a DNA segment that contains polypeptide-coding sequences isolated away from, or purified free from, total eukaryotic, prokaryotic, and viral genomic DNA. Included within the term “DNA segment” are a polypeptide or polypeptides, DNA segments smaller than a polypeptide, and recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like.
- a DNA segment comprising an isolated or purified heterologous gene refers to a DNA segment including non-HAV coding sequences and, in certain aspects, regulatory sequences, isolated substantially away from other naturally occurring genes or protein encoding sequences.
- the term "gene” is used for simplicity to refer to a functional protein, polypeptide or peptide encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences, cDNA sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins and mutants.
- isolated substantially away from other coding sequences means that the gene of interest, in this case, a heterologous gene, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally- occurring coding DNA, such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.
- cDNA is intended to refer to DNA prepared using RNA as a template.
- cDNA can be prepared from either genomic DNA transcribed into mRNA, which is advantageous because the cDNA contains primarily coding sequences, or it can be prepared from genomic RNA, as is found in HAV.
- the term "consecutive nucleic acid segment” will be understood to include a contiguous nucleic acid sequence of at least about 8, about, 9, about 10, about 11, about 12, about 13, about 14, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240, about 250, about 260, about 270, about 280, about 290, about 300, about 310, about 320, about 330, about 340, about 350, about 360, about 370, about 380, about 390, about 400, about 410, about 420, about 430, about 440, about 450, about 460, about 470, about 480, about 490, about 500, about 600, about 700, about 800, about 900, or about 1000,
- the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences that encode the HAV genome and/or a heterologous polypeptide or peptide that includes within its amino acid sequence a contiguous amino acid sequence in accordance with, or essentially corresponding to the named polypeptides
- codons that encode the same amino acid, such as the six codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids.
- the codons are shown in preference of use from left to right, in Table 1. The most preferred codon for alanine is thus "GCC,” and the least is “GCG” (see Table 1, below).
- amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned.
- the addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes.
- nucleic acid segments of the present invention may be combined with other DNA sequences, such as promoters, enhancers, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.
- nucleic acid fragments may be prepared that include a contiguous stretch of nucleotides identical to or complementary to the known sequence for the HAV genome or a heterologous nucleic acid, such as about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about
- nucleotide segments of a million bases or more, including chromosome sized pieces of DNA are contemplated as being useful.
- DNA segments with total lengths of about 1,000, about 500, about 200, about 100 and about 50 base pairs in length (including all intermediate lengths) are also contemplated to be useful.
- intermediate lengths means any length between the quoted ranges, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through the 200-500; 500-1,000; 1,000-2,000; 2,000-3,000; 3,000-5,000; 5,000-10,000 ranges, up to and including sequences of about 12,001, 12,002, 13,001, 13,002, 15,000, 20,000 and the like.
- nucleic acid segments used in the present invention may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.
- modified bases are also contemplated for use in particular applications of the present invention.
- a table of exemplary, but not limiting, modified bases is provided herein below.
- site-specific mutagenesis also has use in the present invention.
- some mutations are known to confer desirable characteristics, for example, high titer growth in cell culture, onto the wild-type HAV genome. See U.S. Patent No. 5,478,746.
- the wild-type genome could be specifically mutagenized at particular places in the HAV genome, and then the mutagenized genome could be used in the claimed methods of the present invention to identify recombinant HAV and HAV variants with even more enhanced characteristics.
- Site-specific mutagenesis is a technique useful in the preparation of proteins or peptides with essentially the same function as the non-mutant nucleic acid sequence, but with alterations in the activity of the protein or peptide, through specific mutagenesis of the underlying DNA.
- the technique further provides a ready ability to prepare and test sequence variants, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA.
- Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed.
- a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.
- site-specific mutagenesis is generally well known in the art.
- the technique typically employs a bacteriophage vector that exists in both a single stranded and double stranded form.
- Typical vectors useful in site-directed mutagenesis include vectors such as the Ml 3 phage. These phage vectors are commercially available and their use is generally well known to those skilled in the art.
- Double stranded plasmids are also routinely employed in site directed mutagenesis, which eliminates the step of transferring the gene of interest from a phage to a plasmid.
- site-directed mutagenesis is performed by first obtaining a single-stranded vector, or melting of two strands of a double stranded vector which includes within its sequence a polynucleotide sequence encoding the desired protein.
- An oligonucleotide primer bearing the desired mutated sequence is synthetically prepared. This primer is then annealed with the single-stranded DNA preparation, and subjected to DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand.
- DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment
- This heteroduplex vector is then used to transform appropriate cells, such as E. coli cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.
- appropriate cells such as E. coli cells
- clones are selected that include recombinant vectors bearing the mutated sequence arrangement.
- sequence variants of the selected gene using site-directed mutagenesis is provided as a means of producing potentially useful species and is not meant to be limiting, as there are other ways in which sequence variants of genes may be obtained.
- recombinant vectors encoding the desired gene may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants.
- the present invention uses vectors comprising DNA sequences to produce recombinant HAV, recombinant HAV variants, and HAV vaccine seed virus.
- cDNA from the HAV RNA genome has been made and placed into vectors that can then be manipulated by standard recombinant methodologies (U.S. Patent No. 5,837,260 and 5,478,746, herein incorporated by reference).
- the term "vector” is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated.
- Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs).
- expression vector refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. Expression vectors can contain a variety of "control sequences,” which refers to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism.
- control sequences may be obtained from any prokaryote, eukaryote, or virus, and they may be joined to other sequences using standard molecular biology techniques.
- restriction enzymes may be employed to digest or cleave a nucleic acid sequence at a particular location.
- the HAV genome is cleaved between the 2A and 2B coding regions. Once cleaved, exogenous or heterologous nucleic acid sequences can be ligated to or joined at the cleavage sites.
- a “promoter” is a control sequence that is a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases “operatively positioned,” “operatively linked,” “under control,” and
- under transcriptional control mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and/or expression of that sequence.
- a promoter may or may not be used in conjunction with an "enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.
- a promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon.
- an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence.
- certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant and/or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment.
- a recombinant and/or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment.
- Such promoters or enhancers may include promoters or enhancers of other genes, and or promoters or enhancers isolated from any other prokaryotic, viral, and/or eukaryotic cell, and/or promoters or enhancers not "naturally occurring," i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression.
- sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCRTM, in connection with the compositions disclosed herein (see U.S. Patent 4,683,202, U.S. Patent 5,928,906, each incorporated herein by reference).
- HAV promoters and/or enhancers can be used to direct proper expression of the HAV gene products; alternatively, liver-specific promoters or enhancer may be employed to direct the expression of a heterologous nucleic acid sequence for use in liver- specific gene therapy.
- liver-specific promoters or enhancer may be employed to direct the expression of a heterologous nucleic acid sequence for use in liver- specific gene therapy.
- promoters, enhancers, and/or cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook et al. (1989), incorporated herein by reference.
- the promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides.
- promoters may be employed that are compatible with in vitro transcription techniques, such as the T3, T7, and SP6 promoters.
- RNA transcription kits that can be used to transcribe an expression construct containing at least one of these promoters are available commercially and are well known to those of skill in the art.
- expression constructs containing a T3, T7, or SP6 promoter are use to transcribe HAV cDNA sequences into RNA that can be transfected into a host cell.
- RNA product refers to an RNA molecule that is the production of a transcription reaction, which includes in vitro reactions.
- Tables 2 lists several elements/promoters that may be employed, in the context of the present invention, to regulate the expression of a gene. This list is not intended to be exhaustive of all the possible elements involved in the promotion of expression but, merely, to be exemplary thereof.
- Table 3 provides examples of inducible elements, which are regions of a nucleic acid sequence that can be activated in response to a specific stimulus.
- tissue-specific promoters or elements as well as assays to characterize their activity, is well known to those of skill in the art. Examples of such regions include the human LIMK2 gene (Nomoto et al. 1999), the somatostatin receptor 2 gene (Kraus et al, 1998), murine epididymal retinoic acid-binding gene (Lareyre et al , 1999).
- human CD4 Zhao- Emonet et al, 1998), mouse alpha2 (XI) collagen (Tsumaki, et al , 1998), D1A dopamine receptor gene (Lee, et al, 1997), insulin-like growth factor II (Wu et al , 1997), human platelet endothelial cell adhesion molecule-1 (Almendro et al, 1996).
- a liver-specific promoter could be particularly useful in the context of the present invention to drive the expression of the HAV genome and/or a heterologous nucleic acid sequence.
- a cDNA insert is employed in the present invention to encode a heterologous nucleic acid sequence
- the nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed such as human growth hormone and SV40 polyadenylation signals.
- Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.
- a vector could encode the amp r gene, which confers resistance to the antibiotic ampicillin. Bacteria can be transformed with this vector, and positive transformants can be selected on ampicillin-containing media.
- the cells contain nucleic acid construct of the present invention, a cell may be identified in vitro or in vivo by including a marker in the expression vector. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector.
- a drug selection marker aids in cloning and in the selection of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers.
- enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be employed.
- Immunologic markers also can be employed.
- the selectable marker employed in the vector backbone is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable markers are well known to one of skill in the art.
- IRES elements are used to create multigene, or polycistronic, messages.
- IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988).
- IRES elements from two members of the picornavirus family polio and encephalomyocarditis have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991).
- IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message.
- Any heterologous open reading frame can be linked to IRES elements. This includes genes for secreted proteins, multi-subunit proteins, encoded by independent genes, intracellular or membrane-bound proteins and selectable markers. In this way, expression of several proteins can be simultaneously engineered into a cell with a single vector and a single selectable marker.
- non-regulatory sequences may also be added to a vector to alow the resulting vector to be manipulated.
- a proteinase cleavage site such as the HAV 3C proteinase cleavage site located in a position not normally found with respect to the HAV genome, is ligated into the genome.
- Other proteinase cleavage sites could be utilized to allow polypeptides to be easily cleaved, as is sometimes the case with fusion proteins.
- linkers could be inserted into a nucleic acid sequence. Linkers include restriction enzyme linkers as well as linkers such as a gly-gly hinge that confers flexibility in any polypeptide containing it.
- the present invention employs expression constructs that encode the HAV genome.
- the constructs are introduced into permissive cells to enable the production of a functional Hepatitis A Virus, which is infectious.
- the description of viral vectors is provided to disclose ways of constructing viral vectors such as an HAV viral vector for use in gene therapy (see also U.S. Patent Nos. 5,670,488 and 5,856,152, incorporated herein by reference).
- the expression vector comprises a virus or engineered vector derived from a viral genome.
- the development of viral vectors is an improvement to the field of gene transfer, as demonstrated by U.S. Patent Application No. 60/078205, hereby incorporated by reference.
- the ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells
- Adenovirus expression vector is meant to include those vectors containing adenovirus sequences sufficient to (a) support packaging of the vector and (b) to express a polynucleotide that has been cloned therein. In this context, expression may require that the gene product be synthesized.
- Adenovirus is particularly suitable for use as a gene transfer vector because of its midsized genome, ease of manipulation, high titer, wide target cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging.
- ITRs inverted repeats
- the early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication.
- the El region (El A and EIB) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes.
- Adenovirus vectors have been used in eukaryotic gene expression (Levrero et al, 1991; Gomez-Foix et al, 1992) and vaccine development (Grunhaus and Horwitz, 1992; Graham and Prevec, 1992). Recently, animal studies suggested that recombinant adenovirus could be used for gene therapy (Stratford-Perricaudet and Perricaudet, 1991; Stratford-Perricaudet et al, 1990; Rich et al, 1993).
- the retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse- transcription (Coffin, 1990).
- the resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins.
- the integration results in the retention of the viral gene sequences in the recipient cell and its descendants.
- the retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively.
- a sequence found upstream from the gag gene contains a signal for packaging of the genome into virions.
- Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and also are required for integration in the host cell genome
- a nucleic acid encoding a gene of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective.
- a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann et al,
- Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind et al, 1975).
- viral vectors may be employed as expression constructs in the present invention.
- Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al, 1988) adeno-associated virus (AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpesviruses may be employed.
- viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al, 1988)
- AAV adeno-associated virus
- herpesviruses may be employed.
- These different viral vectors offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al , 1988; Horwich et al, 1990).
- Non-viral methods for the transfer of expression vectors into cultured mammalian cells include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al, 1986; Potter et al, 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley et al, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer et al, 1987), gene bombardment using high velocity microprojectiles (Yang et al,
- the nucleic acid encoding the gene of interest may be positioned and expressed at different sites.
- the nucleic acid encoding the gene may be stably integrated into the genome of the cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation).
- the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle.
- the expression vector may simply consist of naked recombinant DNA or plasmids. Transfer of the vector may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer in vitro but it may be applied to in vivo use as well. Dubensky et al. (1984) successfully injected polyomavirus DNA in the form of calcium phosphate precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection.
- Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of calcium phosphate-precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a gene of interest also may be transferred in a similar manner in vivo and express the gene product.
- a naked DNA expression vector into cells may involve particle bombardment.
- This method depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein et al, 1987).
- Several devices for accelerating small particles have been developed.
- One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang et al, 1990).
- the microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.
- Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded in vivo (Yang et al, 1990; Zelenin et al , 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ, i.e., ex vivo treatment.
- DNA encoding a particular heterologous gene, or fragments thereof may be delivered via this method and still be incorporated by the present invention.
- the expression vector may be entrapped in a liposome.
- Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers
- Liposome-mediated nucleic acid delivery and expression of foreign DNA in vitro has been very successful. Wong et al, (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells.
- the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda et al, 1989).
- the liposome may be complexed or employed in conjunction with nuclear non- histone chromosomal proteins (HMG-1) (Kato et al, 1991).
- HMG-1 nuclear non- histone chromosomal proteins
- the liposome may be complexed or employed in conjunction with both HVJ and HMG-1.
- expression vectors have been successfully employed in transfer and expression of nucleic acid in vitro and in vivo, then they are applicable for the present invention.
- a bacterial promoter is employed in the DNA vector, it also will be desirable to include within the liposome an appropriate bacterial polymerase.
- receptor-mediated delivery vehicles that can be employed to deliver a nucleic acid encoding a particular gene into cells. These take advantage of the selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993).
- Receptor-mediated gene targeting vehicles generally consist of two components: a cell receptor-specific ligand and a DNA-binding agent.
- ligands have been used for receptor-mediated gene transfer. The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner et al, 1990).
- ASOR asialoorosomucoid
- transferrin Wang and Wu, 1990
- a synthetic neoglycoprotein which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol et al, 1993; Perales et al, 1994) and epidermal growth factor (EGF) also has been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085).
- the delivery vehicle may comprise a ligand and a liposome.
- a ligand and a liposome For example, Nicolau et al, (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes.
- a nucleic acid encoding a particular gene also may be specifically delivered into a cell type such as lung, epithelial or tumor cells, by any number of receptor-ligand systems with or without liposomes.
- epidermal growth factor may be used as the receptor for mediated delivery of a nucleic acid encoding a gene in many tumor cells that exhibit upregulation of EGF receptor.
- Mannose can be used to target the mannose receptor on liver cells.
- antibodies to CD5 (CLL), CD22 (lymphoma), CD25 (T-cell leukemia) and MAA (melanoma) can similarly be used as targeting moieties.
- gene transfer may more easily be performed under ex vivo conditions.
- Ex vivo gene therapy refers to the isolation of cells from an animal, the delivery of a nucleic acid into the cells in vitro, and then the return of the modified cells back into an animal. This may involve the surgical removal of tissue/organs from an animal or the primary culture of cells and tissues.
- Continuous perfusion of an expression vector or a viral vector also is contemplated.
- the amount of vector or peptide delivered in continuous perfusion can be determined by the amount of uptake that is desirable.
- the present invention utilizes expression constructs encoding the HAV genome to produce an infectious recombinant HAV.
- the constructs are introduced into cells, cell cultures, or cell lines. While various mammalian host cell lines such as HeLa, HepG2, 3T3, MDCK can be used, cells most frequently used with the current invention are cells permissive for HAV.
- a permissive cell is one that supports the replication of HAV and that frequently, as a consequence, undergoes lysis. These lines include MRC-5, a diploid human line suitable for production of human vaccines, Vero cells, BSC-1, and FRhK-4.
- the present invention contemplates that these permissive cells could be used for infection by recombinant HAV virus for a number of purposes, including the use of these cells to assay HAV activity.
- Primary mammalian cell cultures may be prepared in various ways. In order for the cells to be kept viable while in vitro and in contact with the expression vector, it is necessary to ensure that the cells maintain contact with the correct ratio of oxygen and carbon dioxide and nutrients but are protected from microbial contamination. Cell culture techniques are well documented and are disclosed herein by reference (Freshney, 1992). Furthermore, the present invention sometimes requires that the cells be cultured under conditions that permit HAV replication. Such conditions are well known to those of skill in the art.
- a cell such as resistance to a drug.
- increasing concentration levels of a drug in media are exposed to cells, some of which may contain a drug resistance marker. Cells expressing that marker can survive certain concentration levels, but there may become a point at which the concentration level increases so much that only cells that mutate to accommodate the higher levels are viable. A skilled artisan would be able to increase the concentration in increments that permits such mutations to occur.
- the present invention contemplates cloning heterologous nucleic acid sequences including genes or cDNAs from mammalian tissue or cells for use in recombinant HAV, HAV variants, and HAV vaccine seed virus.
- a technique often employed by those skilled in the art of protein production today is to obtain a so-called "recombinant" version of the protein, to express it in a recombinant cell and to obtain the protein from such cells.
- These techniques are based upon the cloning of a DNA molecule encoding the protein from a DNA library, i.e., on obtaining a specific DNA molecule distinct from other portions of DNA. This can be achieved by, for example, cloning a cDNA molecule, or cloning a genomic-like DNA molecule.
- the first step in such cloning procedures is the screening of an appropriate DNA library, for example, human liver cells.
- the screening protocol may utilize nucleotide segments or probes that are designed to hybridize to cDNA or genomic sequences of a particular heterologous nucleic acid of interest. Additionally, antibodies designed to bind to the expressed heterologous proteins, polypeptides, or peptides may be used as probes to screen an appropriate DNA expression library. Alternatively, activity assays may be employed.
- the operation of such screening protocols are well known to those of skill in the art and are described in detail in the scientific literature, for example, in Sambrook et al. (1989), incorporated herein by reference.
- genomic segments as well as cDNA molecules
- suitable genomic cloning methods may also be used.
- “designed to hybridize” means a sequence selected for its likely ability to hybridize to the heterologous nucleic acid sequence of interest, for example due to a expected high degree of homology between another organism and the desired human genes. Also included are segments or probes altered to enhance their ability to hybridize to or bind to a heterologous sequence of choice.
- these regions of homology also include amino acid sequences of 4 or more consecutive amino acids selected and/or altered to increase conservation of the amino acid sequences in comparison to the same or similar region of residues in the same or related genes in one or more species.
- the term "designed to bind" in refers to an antibody that is selected for its likely ability to bind the desired heterologous protein, polypeptides, peptides, or antigenic fragments thereof, particularly during a screening assay for the target gene, including amino acids altered to increase antigenicity.
- the present invention may also involve the use of various nucleic acid detection methods. Such methods could be used, for example, to identify whether a heterologous nucleic acid sequence is contained within a particular recombinant HAV or to characterize an HAV variant that has enhanced growth properties by identifying any mutations in the HAV genome. Nucleic acid detection methods are well known to those of skill in the art. Some of these methods are presented below.
- Hybridization The use of a hybridization probe of between 17 and 100 nucleotides in length, or in some aspect of the invention even up to 1-2 Kb or more in length, allows the formation of a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 20 bases in length are generally preferred, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of particular hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having stretches of
- Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means or by introducing selected sequences into recombinant vectors for recombinant production.
- the use if hybridization can be used to confirm the presence of a particular sequence.
- relatively stringent conditions e.g., one will select relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50°C to about 70°C.
- hybridization may be achieved under conditions of, for example,
- nucleic acid sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization.
- appropriate indicator means include fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of being detected.
- colorimetric indicator substrates are known that can be employed to provide a detection means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid- containing samples.
- the hybridization probes described herein will be useful both as reagents in solution hybridization, as in PCRTM, for detection of expression of corresponding genes, as well as in embodiments employing a solid phase.
- the test DNA or RNA
- the selected conditions will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridized surface to remove non-specifically bound probe molecules, hybridization is detected, or even quantified, by means of the label.
- Nucleic acid used as a template for amplification is isolated from cells contained in the biological sample, according to standard methodologies (Sambrook et l, 1989).
- the nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to convert the RNA to a complementary DNA.
- the RNA is whole cell RNA and is used directly as the template for amplification.
- PCRTM polymerase chain reaction
- LCR ligase chain reaction
- SDA Strand Displacement Amplification
- RCR Repair Chain Reaction
- nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR (Gingeras et al, PCT Application WO 88/10315, incorporated herein by reference). Davey et al, EPA No. 329 822 (incorporated herein by reference in its entirety) disclose a different nucleic acid amplification process, which may be used in accordance with the present invention.
- TAS transcription-based amplification systems
- NASBA nucleic acid sequence based amplification
- 3SR Genomerase et al
- Davey et al EPA No. 329 822 (incorporated herein by reference in its entirety) disclose a different nucleic acid amplification process, which may be used in accordance with the present invention.
- visualization is achieved indirectly.
- a labeled, nucleic acid probe is brought into contact with the amplified marker sequence.
- the probe preferably is conjugated to a chromophore but may be radiolabeled.
- the probe is conjugated to a binding partner, such as an antibody or biotin, and the other member of the binding pair carries a detectable moiety.
- detection is by Southern blotting and hybridization with a labeled probe.
- the techniques involved in Southern blotting are well known to those of skill in the art and can be found in many standard books on molecular protocols. See Sambrook et al, 1989.
- DGGE denaturing gradient gel electrophoresis
- SSCP single-strand conformation polymorphism analysis
- mismatch is defined as a region of one or more unpaired or mispaired nucleotides in a double-stranded RNA/RNA, RNA DNA or DNA/DNA molecule. This definition thus includes mismatches due to insertion/deletion mutations, as well as single and multiple base point mutations.
- U.S. Patent No. 4,946,773 describes an RNase A mismatch cleavage assay that involves annealing single-stranded DNA or RNA test samples to an RNA probe, and subsequent treatment of the nucleic acid duplexes with RNase A. After the RNase cleavage reaction, the RNase is inactivated by proteolytic digestion and organic extraction, and the cleavage products are denatured by heating and analyzed by electrophoresis on denaturing polyacrylamide gels. For the detection of mismatches, the single-stranded products of the RNase A treatment, electrophoretically separated according to size, are compared to similarly treated control duplexes. Samples containing smaller fragments (cleavage products) not seen in the control duplex are scored as positive.
- RNase mismatch cleavage assays including those performed according to U.S. Patent No. 4,946,773, require the use of radiolabeled RNA probes.
- Myers and Maniatis in U.S. Patent No. 4,946,773 describe the detection of base pair mismatches using RNase A.
- Other investigators have described the use of an E. coli enzyme, RNase I, in mismatch assays. Because it has broader cleavage specificity than RNase A, RNase I would be a desirable enzyme to employ in the detection of base pair mismatches if components can be found to decrease the extent of non-specific cleavage and increase the frequency of cleavage of mismatches.
- RNase I for mismatch detection is described in literature from P OM ⁇ GA® Biotech. PR0M ⁇ GA®markets a kit containing RNase I that is shown in their literature to cleave three out of four known mismatches, provided the enzyme level is sufficiently high.
- the RNase protection assay was first used to detect and map the ends of specific mRNA targets in solution.
- the assay relies on being able to easily generate high specific activity radiolabeled RNA probes complementary to the mRNA of interest by in vitro transcription.
- the templates for in vitro transcription were recombinant plasmids containing bacteriophage promoters.
- the probes are mixed with total cellular RNA samples to permit hybridization to their complementary targets, then the mixture is treated with RNase to degrade excess unhybridized probe.
- the RNase used is specific for single- stranded RNA, so that hybridized double-stranded probe is protected from degradation. After inactivation and removal of the RNase, the protected probe (which is proportional in amount to the amount of target mRNA that was present) is recovered and analyzed on a polyacrylamide gel.
- the RNase protection assay was adapted for detection of single base mutations.
- radiolabeled RNA probes transcribed in vitro from wild-type sequences are hybridized to complementary target regions derived from test samples.
- the test target generally comprises DNA (either genomic DNA or DNA amplified by cloning in plasmids or by PCRTM), although RNA targets have occasionally been used. If single nucleotide (or greater) sequence differences occur between the hybridized probe and target, the resulting disruption in Watson-Crick hydrogen bonding at that position ("mismatch") can be recognized and cleaved in some cases by single-strand specific ribonuclease. To date, RNase A has been used almost exclusively for cleavage of single-base mismatches, although RNase I has recently been shown as useful also for mismatch cleavage. There are recent descriptions of using the MutS protein and other DNA-repair enzymes for detection of single-base mismatches.
- Detection methods for nucleic acids can be used to assay various cellular and molecular properties of a cell or a virus.
- One of skill in the art would know how to use the methods described herein to detect enhanced growth.
- the amount of nucleic acid molecules during a particularly time frame could be easily determined using nucleic acid amplification techniques.
- the present invention covers the expression of proteins, polypeptides, or peptides encoded by the HAV genome and heterologous nucleic acid sequences.
- the term "purified" proteins, polypeptides, or peptides as used herein, is intended to refer to a proteinaceous composition, isolatable from mammalian cells or recombinant host cells, wherein the protein, polypeptide, or peptide is purified to any degree relative to its naturally-obtainable state, i.e., relative to its purity within a cellular extract.
- a purified protein, polypeptide, or peptide therefore also refers to a wild-type or mutant protein, polypeptide, or peptide free from the environment in which it naturally occurs.
- polyprotein region is used to refer to a region that encodes at least one gene product, as opposed to a noncoding region.
- the junction between 2A and 2B in teh HAV genome is an example of a polyprotein region.
- Proteinaceous segments of relatively small peptides such as, for example, peptides of from about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 35, about 40, about 45, to about 50 amino acids in length, and more preferably, of from about 15 to about 30 amino acids in length, and also larger polypeptides of from about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240, about 250, about 275, about 300, about 350, about 400
- proteins, polypeptides, or peptides will be subjected to fractionation to remove various components not of interest from the composition.
- fractionation to remove various components not of interest from the composition.
- various other techniques suitable for use in protein purification will be well known to those of skill in the art. These include, for example, precipitation with ammonium sulfate, PEG, antibodies and the like or by heat denaturation, followed by centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite, lectin affinity and other affinity chromatography steps; isoelectric focusing; gel electrophoresis; and combinations of such and other techniques.
- Another example is the purification of particular fusion protein using a specific binding partner.
- Such purification methods are routine in the art. This is exemplified by the generation glutathione S-transferase fusion protein, expression in E. coli, and isolation to homogeneity using affinity chromatography on glutathione-agarose or the generation of a polyhistidine tag on the N- or C-terminus of the protein, and subsequent purification using Ni-affinity chromatography.
- a foreign antigen is encoded by a recombinant HAV.
- the recombinant HAV encodes at least one epitope of an antigen.
- U.S. Patent 4,554,101, (Hopp) incorporated herein by reference, teaches the identification and preparation of epitopes from primary amino acid sequences on the basis of hydrophilicity. Through the methods disclosed in Hopp, one of skill in the art would be able to identify epitopes from within an amino acid sequence such as Us 1.5 sequences disclosed herein in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.
- PepPlot® (Brutlag et al, 1990; Weinberger et al, 1985), and other new programs for protein tertiary structure prediction (Fetrow and Bryant, 1993).
- MacVector IBI, New Haven, CT.
- major antigenic determinants of a polypeptide may be identified by an empirical approach in which portions of the gene encoding the polypeptide are expressed in a recombinant host, and the resulting proteins tested for their ability to elicit an immune response.
- PCRTM can be used to prepare a range of peptides lacking successively longer fragments of the C-terminus of the protein. The immunoactivity of each of these peptides is determined to identify those fragments or domains of the polypeptide that are immunodominant. Further studies in which only a small number of amino acids are removed at each iteration then allows the location of the antigenic determinants of the polypeptide to be more precisely determined.
- polypeptides Another method for determining the major antigenic determinants of a polypeptide is the SPOTsTM system (Genosys Biotechnologies, Inc., The Woodlands, TX). In this method, overlapping peptides are synthesized on a cellulose membrane, which following synthesis and deprotection, is screened using a polyclonal or monoclonal antibody. The antigenic determinants of the peptides which are initially identified can be further localized by performing subsequent syntheses of smaller peptides with larger overlaps, and by eventually replacing individual amino acids at each position along the immunore active peptide. Once one or more such analyses are completed, polypeptides are prepared that contain at least the essential features of one or more antigenic determinants.
- Minigenes or gene fusions encoding these determinants can also be constructed and inserted into expression vectors by standard methods, for example, using PCRTM cloning methodology.
- peptides for antibody generation or vaccination typically requires conjugation of the peptide to an immunogenic carrier protein, such as hepatitis B surface antigen, keyhole limpet hemocyanin or bovine serum albumin. Methods for performing this conjugation are well known in the art.
- an immunogenic carrier protein such as hepatitis B surface antigen, keyhole limpet hemocyanin or bovine serum albumin.
- the present invention utilizes different recombinant HAV constructs, variants and vaccine seed virus.
- assays to identify or characterize the presence of a particular compound are desirable, for example, to determine whether a construct is properly expressing a heterologous gene.
- the present invention concerns immunodetection methods for binding, purifying, removing, quantifying or otherwise generally detecting biological components such as HAV or heterologous polypeptides, peptides, or proteins.
- Antibodies may be employed to detect HAV, or alternatively, antibodies could be used to identify and quantify the level of antigen that a viral variant or vaccine seed virus could produce.
- immunoassays are employed in combination with an HAV variant that has increased viral antigen production for diagnostic assays.
- diagnostic assays involving HAV antigens is described in LaBrecque, 1998, which creates a recombinant HAV antigen.
- the steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Nakamura et al. (1987), incorporated herein by reference.
- the immunobinding methods include obtaining a sample suspected of containing the desired protein, polypeptide or peptide, and contacting the sample with a first antibody in accordance with the present invention, as the case may be, under conditions effective to allow the formation of immunocomplexes.
- the immunobinding methods also include methods for detecting or quantifying the amount of a protein reactive component in a sample, which methods require the detection or quantification of any immune complexes formed during the binding process.
- methods for detecting or quantifying the amount of a protein reactive component in a sample which methods require the detection or quantification of any immune complexes formed during the binding process.
- the chosen biological sample with the antibody under conditions effective and for a period of time sufficient to allow the formation of immune complexes is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time lone enough for the antibodies to form immune complexes with, i.e., to bind to any protein antigens present.
- the sample-antibody composition such as a tissue section, ELISA plate, dot blot or western blot, will generally be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected.
- the antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined.
- the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody.
- the second binding ligand may be linked to a detectable label.
- the second binding ligand is itself often an antibody, which may thus be termed a "secondary" antibody.
- the primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under conditions effective and for a period of time sufficient to allow the formation of secondary immune complexes.
- the secondary immune complexes are then generally washed to remove any non- specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected. Further methods include the detection of primary immune complexes by a two step approach. A second binding ligand, such as an antibody, that has binding affinity for the antibody is used to form secondary immune complexes, as described above. After washing, the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under conditions effective and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.
- immunoassays in their most simple and direct sense, are binding assays.
- Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art.
- ELISAs enzyme linked immunosorbent assays
- RIA radioimmunoassays
- Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and western blotting, dot blotting, FACS analyses, and the like may also be used.
- the appropriate antibodies are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the antigen of interest is added to the wells. After binding and washing to remove non-specifically bound immune complexes, the bound protein antigen may be detected. Detection is generally achieved by the addition of a secondary antibody recognizing the first antibody and that is linked to a detectable label. This type of ELISA is a simple "sandwich ELISA.” Detection may also be achieved by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.
- ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described in more detail below.
- a plate with either antigen or antibody In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of h. The wells of the plate will then be washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera. These include bovine serum albumin (BSA), casein and solutions of milk powder.
- BSA bovine serum albumin
- the coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.
- a secondary or tertiary detection means rather than a direct procedure.
- the immobilizing surface is contacted with the biological sample to be tested under conditions effective to allow immune complex (antigen/antibody) formation. Detection of the immune complex then requires a labeled secondary binding ligand or antibody, or a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or third binding ligand.
- Under conditions effective to allow immune complex (antigen/antibody) formation means that the conditions preferably include diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.
- BSA bovine gamma globulin
- PBS phosphate buffered saline
- suitable conditions also mean that the incubation is at a temperature and for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 h or so, at temperatures preferably on the order of 25°C to 27°C, or may be overnight at about 4°C or so.
- the contacted surface is washed so as to remove non-complexed material.
- a preferred washing procedure includes washing with a solution such as PBS/Tween, or borate buffer. Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.
- the second or third antibody will have an associated label to allow detection.
- this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate.
- a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immune complex formation (e.g., incubation for 2 h at room temperature in a PBS-containing solution such as PBS-Tween).
- the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6- sulfonic acid (ABTS) and H 2 O 2 , in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer.
- a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6- sulfonic acid (ABTS) and H 2 O 2 , in the case of peroxidase as the enzyme label.
- Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer.
- the immunoassays described herein could be implemented to detect and quantify viral antigen production. Similarly, these methods could be used to detect whether viral replication occurs more quickly by targetting a number of marker proteins that are affected by viral replication.
- ntibodies may also be used in conjunction with both fresh-frozen and formalin-fixed, paraffin- embedded tissue blocks prepared for study by immunohistochemistry (IHC).
- IHC immunohistochemistry
- HAV genes and proteins as well as heterologous nucleic acid sequences and proteins, of the present invention, and still allow molecules having like or otherwise desirable characteristics to be obtained, such biologically functional equivalents are also encompassed within the present invention.
- amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies, binding sites on substrate molecules or receptors, or such like. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence (or, of course, its underlying DNA coding sequence) and nevertheless obtain a protein with like (agonistic) properties. It is thus contemplated that various changes may be made in the sequence HAV proteins, polypeptides or peptides, or the underlying nucleic acids, without appreciable loss of their biological utility or activity.
- biologically functional equivalents In terms of functional equivalents, it is well understood by the skilled artisan that, inherent in the definition of a "biologically functional equivalent" protein or peptide or gene, is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity. Biologically functional equivalent peptides are thus defined herein as those peptides in which certain, not most or all, of the amino acids may be substituted.
- Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
- An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape.
- arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically functional equivalents.
- hydropathic index of amino acids may be considered.
- Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
- hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ⁇ 2 is preferred, those which are within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly preferred.
- peptide mimetics may be used in the same manner as the peptides of the invention and hence are also functional equivalents.
- Certain mimetics that mimic elements of protein secondary structure are described in Johnson et al. (1993).
- the underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orientate amino acid side chains in such a way as to facilitate molecular interactions, such as those of antibody and antigen.
- a peptide mimetic is thus designed to permit molecular interactions similar to the natural molecule.
- ⁇ -turn structure within a polypeptide can be predicted by computer-based algorithms, as discussed herein. Once the component amino acids of the turn are determined, mimetics can be constructed to achieve a similar spatial orientation of the essential elements of the amino acid side chains.
- modified or unusual amino acids are also contemplated for use in the present invention.
- a table of exemplary, but not limiting, modified or unusual amino acids is provided herein below.
- Some of the embodiments of the present invention involve a recombinant HAV that contains a heterologous sequence and methods of making the recombinant HAV. While recombinant technology can be utilized to create a vector that itself is used to produce HAV, common virology techniques and methods may also be required to practice the claimed invention. For example, methods of creating an attenuated, cell culture- adapted version of HAV can be created using a vector encoding the HAV genome according to methods known to those of skill in the art, according to U.S. Patent No. 5,837,260 and 5,478,746, each incorporated by reference.
- While propagation of a recombinant HAV may require that the vector be introduced or transfected into a cell, particularly a permissive one, conditions that effect propagation and/or replication of the virus may be employed. Such conditions are well known to those of skill in the art.
- the virus can be propagated by directly infecting a permissive cell under conditions to effect replication.
- a skilled virologist would be familiar with techniques that can be used to determine factors influencing infectivity such as multiplicity of infection (MOI), as well as those that can be used to evaluate efficacy of infection, such as the number of particle forming units (pfu).
- substantially purified is used with respect to a recombinant HAV, this will refer to a composition in which recombinant HAV forms the major component of the composition, such as constituting about 50% of the proteins in the composition or more.
- a substantially purified virus will constitute more than 60%, 70%, 80%, 90%, 95%, 99% or even more of the proteins in the composition.
- a virus that is "purified to homogeneity," as applied to the present invention, means that the peptide, polypeptide or protein has a level of purity where the peptide, polypeptide or protein is substantially free from other proteins and biological components.
- a purified peptide, polypeptide or protein will often be sufficiently free of other protein components so that degradative sequencing may be performed successfully.
- compositions expression vectors, virus stocks, polypeptides, peptides, antibodies, and drugs—in a form appropriate for the intended application.
- this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.
- compositions of the present invention comprise an effective amount of the vector to cells, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such compositions also are referred to as inocula.
- pharmaceutically or pharmacologically acceptable refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutically active substances is well know in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
- compositions of the present invention may include classic pharmaceutical preparations. Administration of these compositions according to the present invention will be via any common route so long as the target tissue is available via that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions, described supra.
- the expression vectors and delivery vehicles also may be administered parenterally or intraperitoneally.
- Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- compositions of the present invention are advantageously administered in the form of injectable compositions either as liquid solutions or suspensions; solid forms suitable for solution in. or suspension in, liquid prior to injection may also be prepared. These preparations also may be emulsified.
- a typical composition for such purpose comprises a pharmaceutically acceptable carrier.
- the composition may contain 10 mg, 25 mg, 50 mg or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline.
- Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc.
- Intravenous vehicles include fluid and nutrient replenishers.
- Preservatives include antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components the pharmaceutical composition are adjusted according to well known parameters.
- Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like.
- the compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
- the route is topical, the form may be a cream, ointment, salve or spray.
- an effective amount of the therapeutic agent is determined based on the intended goal, for example (i) immunity to HAV or (ii) treatment of a liver-specific condition or disease.
- unit dose refers to physically discrete units suitable for use in a subject, each unit containing a predetermined-quantity of the therapeutic composition calculated to produce the desired responses, discussed above, in association with its administration, i.e., the appropriate route and treatment regimen.
- the quantity to be administered both according to number of treatments and unit dose, depends on the subject to be treated, the state of the subject and the protection desired. Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual.
- the recombinant hepatitis A viruses of the present invention may be administered directly into animals and humans, or alternatively, administered to cells that are subsequently administered to these organisms.
- the viruses can be combined with the various ⁇ -interferon inhibiting formulations to produce transducing formulations with greater transduction efficiencies.
- liposomes and/or nanoparticles are contemplated for the introduction of recombinant HAV, protein, polypeptides, peptides or agents, or gene therapy vectors into host cells.
- HAV recombinant virus
- protein protein
- polypeptides peptides or agents
- gene therapy vectors gene therapy vectors
- Nanocapsules can generally entrap compounds in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 ⁇ m) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention, and such particles may be are easily made.
- Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4 ⁇ m. Sonication of MLVs
- MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 A, containing an aqueous solution in the core.
- SUVs small unilamellar vesicles
- Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure.
- the physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state.
- Liposomes interact with cells via four different mechanisms: Endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. Varying the liposome formulation can alter which mechanism is operative, although more than one may operate at the same time.
- in vitro administration refers to manipulations performed on cells removed from an animal, including, but not limited to, cells in culture.
- ex vivo administration refers to cells which have been manipulated in vitro, and are subsequently administered to a living animal.
- in vivo administration includes all manipulations performed on cells within an animal.
- compositions may be administered either in vitro, ex vivo, or in vivo.
- hepatocytes are incubated with a recombinant HAV of the instant invention for 24 to 48 hours.
- the transduced cells can then be used for in vitro analysis, or alternatively for in vivo administration.
- compositions of the present invention also are contemplated.
- examples include, but are not limited to, transduction of liver cells by infusion of appropriate transducing compositions through the portal vein via a catheter (Bao et al, 1996). Additional examples include direct injection of tumors with the instant transducing compositions, and either intranasal or intratracheal (Dong et al, 1996) instillation of transducing compositions to effect transduction of lung cells.
- infectious hepatitis A virus cDNA clone used for construction of a viral genome encoding a selectable marker was constructed by insertion of cDNA segments cloned from a highly cell culture-adapted variant of hepatitis A virus (HM175/18f, Zhang et al, 1996) into a prototype infectious cDNA obtained from the National Institute of Health (pHAV/7, Cohen et al, 1986).
- HM175/18f hepatitis A virus
- One embodiment of the present invention was forced selection of an HAV HM175 strain variant that is capable of enhanced antigen yield in MRC-5 cells. This was achieved by addition of a sequence encoding a selectable marker (zeo) within the HAV polyprotein, at the primary polyprotein cleavage site located between the 2 A and 2B coding region (FIG. 1). The specific construction was carried out within a plasmid containing an infectious cDNA copy of the HM175/18f genome (Zhang et al. 1996).
- zeo selectable marker
- the zeo coding sequence amplified PCRTM from a vector supplied by InVitrogen, was flanked by artificially constructed HAV 3C proteinase cleavage sites, and this cassette was inserted in frame at the normal 2A/2B cleavage site (FIG. 1).
- a gly-gly hinge was also included in each of the flanking cleavage sites to increase polypeptide chain flexibility and facilitate efficient cleavage. Construction of this cDNA was completed and synthetic RNA derived from 2 sister cDNA constructs was individually transfected into permissive FRh-K4 cells with recovery of viable virus. Virus was recovered from both transfections, as determined by radioimmunofocus assay on BSC-1 cells with foci that were approximately 2-fold smaller than the parent HM175/18f virus foci (in effect small plaque variants, FIG. 1).
- the present invention comprises a more efficient production of viral antigen that would enhance vaccine production, thus lowering unit production costs and potentially increasing vaccine doses produced per cm of cell culture area.
- HAV containing zeo was used to infect BSC-1 cells. Selection of HAV variants was performed by culturing infected cells in the presence of increasing concentrations of the antibiotic Zeocin (50-500 ⁇ g/ml). Virus was harvested and its replication potential determined by radioimmunofocus assay in BSC-1 cells. As a control, parallel cultures were infected with parent virus HM175/18f. Cell death was observed at concentrations of Zeocin >250 ⁇ g/ml, however cultures infected with HAV containing the Zeo gene showed greater resistance (i.e. increased numbers of viable cells remained for a longer period of time) to Zeocin compared with cultures infected with the parent virus, HM175/18f.
- the primary polyprotein cleavage event in HAV most likely occurs at the 2A 2B junction in contrast to poliovirus in which cleavage occurs at the P1/P2 junction.
- synthesis of PI -2 A could be uncoupled from that of 2BC-P3 we constructed a dicistronic HAV genome containing the EMCV IRES between the 2A and 2B proteins. Insertion of the EMCV IRES did not affect polyprotein processing in vitro. However, transfection of synthetic T7 derived RNA into permissive FRhK-4 cells demonstrated that this RNA had a replication-defective phenotype.
- a nucleotide sequence encoding a heterologous protein was introduced into the HAV genome at the 2A/2B site.
- the gene encoding the selectable marker zeo (ble) was flanked by HAV 3C pro cleavage sites a placed in-frame between the 2 A and 2B proteins (Gin /Ala ). Replication of HAV RNA containing the zeo gene was observed in
- BSC-1 cells by radioimmunofocus assay with a replication phenotype that was slightly reduced compared to the parent HM 175- 18f virus.
- the zeo gene was retained for up to 5 passages in BSC-1 cells as determined by RT/PCR. This is the first demonstration that foreign sequence can be inserted at this site and result in a viable virus phenotype.
- These results confirm that the 2A/2B junction is the primary cleavage site and suggest that other foreign antigens may be engineered at this site in the HAV genome and allow liver specific expression of a foreign gene.
- EXAMPLE 2 The selection HAV viral variants described for BSC-1 cells has been extended to MRC- 5 cells, the cells used to manufacture the current HAV vaccine.
- EXAMPLE 3 The insertion of other foreign coding sequences at the 2A/2B junction has also been explored, in the same context as the zeo gene. This has been done to test the size of the insert that can be tolerated by the HAV genome as similar experience with poliovirus has suggested that as you increase the size of the insert the stability of the recombinant virus decreases, resulting in removal of the inserted sequence.
- the GFP (green fluorescent protein) and the Renilla Luciferase gene have been inserted into the 2A/2B junction of HAV in similar context to that of the zeo gene described above.
- HM175/18f Stability of the insertion was addressed by RT/PCR using primers that span the insertion. RT/PCR results indicated that insertion of increasingly larger sequences (up to 950bp) within the HAV genome at 2A/2B junction resulted in genetic instability and removal of all or part of the inserted sequence after 3-4 passages. Nevertheless, these results indicate that insertion of foreign sequences of different sizes can result in a viable virus phenotype.
- Boshart et al Cell, 41 :521, 1985. Bosze et al, EMBO J., 5:1615, 1986.
- Kaneda et al Science, 243:375-378, 1989.
- Karin et al Mol. Cell. Biol, 7:606, 1987.
- Katinka et al Cell, 20:393, 1980.
- Katinka et al. Nature, 290:720, 1981.
- Temin "Retrovirus vectors for gene transfer: Efficient integration into and expression of exogenous DNA in vertebrate cell genome," In: Gene Transfer, Kucherlapati, ed.,
- Vasseur et l Proc. Natl. Acad. Sci. U.S.A., 77:1068, 1980.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9894598P | 1998-09-03 | 1998-09-03 | |
US60/098,945 | 1998-09-03 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2000014263A2 true WO2000014263A2 (en) | 2000-03-16 |
WO2000014263A3 WO2000014263A3 (en) | 2000-08-17 |
WO2000014263A8 WO2000014263A8 (en) | 2001-03-15 |
WO2000014263A9 WO2000014263A9 (en) | 2001-11-22 |
Family
ID=22271678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/020375 WO2000014263A2 (en) | 1998-09-03 | 1999-09-03 | Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2000014263A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921634B2 (en) | 1999-12-23 | 2005-07-26 | Board Of Regents, The University Of Texas System | Replication competent hepatitus C virus and methods of use |
US8026092B2 (en) | 2003-12-01 | 2011-09-27 | Board Of Regents, The University Of Texas System | Replication competent hepatitis C virus and methods of use |
US8871737B2 (en) | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
CN104862287A (en) * | 2015-05-21 | 2015-08-26 | 中国医学科学院医学生物学研究所 | Preparation method of genetic engineering recombinant combined vaccine against hepatitis A and hepatitis E |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994029472A2 (en) * | 1993-06-03 | 1994-12-22 | Institut Pasteur | Mengovirus as a vector for expression of foreign polypeptides |
EP0302801B1 (en) * | 1987-08-07 | 1995-10-18 | Institut Pasteur | Vaccines of which the characteristic epitope is incorporated in a picorna virus protein, particularly in that of the polio virus |
US5478746A (en) * | 1982-04-07 | 1995-12-26 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding attenuated cell culture adapted hepatitis A virus genome |
WO1997040166A2 (en) * | 1996-04-19 | 1997-10-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Simian-human hav having a chimeric 2c protein |
-
1999
- 1999-09-03 WO PCT/US1999/020375 patent/WO2000014263A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478746A (en) * | 1982-04-07 | 1995-12-26 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding attenuated cell culture adapted hepatitis A virus genome |
EP0302801B1 (en) * | 1987-08-07 | 1995-10-18 | Institut Pasteur | Vaccines of which the characteristic epitope is incorporated in a picorna virus protein, particularly in that of the polio virus |
WO1994029472A2 (en) * | 1993-06-03 | 1994-12-22 | Institut Pasteur | Mengovirus as a vector for expression of foreign polypeptides |
WO1997040166A2 (en) * | 1996-04-19 | 1997-10-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Simian-human hav having a chimeric 2c protein |
Non-Patent Citations (2)
Title |
---|
TANG S ET AL.: "Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity" JOURNAL OF VIROLOGY, vol. 71, no. 10, October 1997 (1997-10), pages 7841-7850, XP002128739 AMERICAN SOCIETY FOR MICROBIOLOGY US cited in the application * |
ZELL R ET AL: "COXSACKIEVIRUS B3 (CVB3) VARIANTS EXPRESSING CYTOKINE GENES AS A TOOL TO INFLUENCE THE LOCAL IMMUNITY IN VIVO" IMMUNOBIOLOGY, vol. 197, no. 2/04, 1997, page 336 XP002072834 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921634B2 (en) | 1999-12-23 | 2005-07-26 | Board Of Regents, The University Of Texas System | Replication competent hepatitus C virus and methods of use |
US7288369B2 (en) | 1999-12-23 | 2007-10-30 | Board Of Regents, The University Of Texas System | Replication competent hepatitis C virus and methods of use |
US8367401B2 (en) | 1999-12-23 | 2013-02-05 | Board Of Regents, The University Of Texas System | Replication competent hepatitis C virus and methods of use |
US8026092B2 (en) | 2003-12-01 | 2011-09-27 | Board Of Regents, The University Of Texas System | Replication competent hepatitis C virus and methods of use |
US8871737B2 (en) | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US9278990B2 (en) | 2010-09-22 | 2016-03-08 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US9605018B2 (en) | 2011-12-22 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
US9856284B2 (en) | 2012-03-21 | 2018-01-02 | Alios Biopharma, Inc. | Solid forms of a thiophosphoramidate nucleotide prodrug |
US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
CN104862287A (en) * | 2015-05-21 | 2015-08-26 | 中国医学科学院医学生物学研究所 | Preparation method of genetic engineering recombinant combined vaccine against hepatitis A and hepatitis E |
Also Published As
Publication number | Publication date |
---|---|
WO2000014263A3 (en) | 2000-08-17 |
WO2000014263A8 (en) | 2001-03-15 |
WO2000014263A9 (en) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1004670B1 (en) | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents | |
JP2007502612A (en) | Coronavirus, nucleic acid, protein, and vaccine production methods, drugs and diagnostics | |
US7371525B2 (en) | Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS) | |
JPH07143888A (en) | Shape-specific papillomavirus dna sequence and peptide | |
CN111437384A (en) | Batwing-derived coronavirus vaccine for preventing COVID-19 | |
CH684594A5 (en) | viral agent. | |
CA2197569A1 (en) | Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus | |
CN106456741B (en) | Recombinant Classical Swine Fever Virus (CSFV) comprising a substitution in the TAV epitope of the E2 protein | |
WO2008127840A2 (en) | Flavivirus ns5a proteins for the treatment of hiv | |
CA2125701A1 (en) | Hepatitis e virus vaccine and method | |
AU673135B2 (en) | Non-A, non-B hepatitis virus antigen, diagnostic methods and vaccines | |
JPH08507080A (en) | Peptides that induce cytotoxic T lymphocyte responses to hepatitis B virus | |
WO2000014263A2 (en) | Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them | |
Moreno-Lopez et al. | Reindeer papillomavirus transforming properties correlate with a highly conserved E5 region | |
WO2006110915A2 (en) | Vaccine formulations for leishmania | |
US5800982A (en) | Antigenic peptides for growing hepatitis C virus, kit comprising the same and methods for its grouping using the same | |
JP2000512129A (en) | Pig retrovirus | |
CA2221313A1 (en) | Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus | |
US6870043B2 (en) | Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells | |
KR20230008707A (en) | Vaccine composition for treatment of coronavirus | |
US9388428B2 (en) | Compositions and methods related to viruses of the genus Negevirus | |
WO2007101103A2 (en) | Compositions and assays for inhibiting hcv infection | |
WO2022253340A1 (en) | Peptide translated by circular rna circ-ace2 and application thereof | |
WO2004037202A2 (en) | Gb virus c and methods of treating viral infections | |
AU776955B2 (en) | Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09564065 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
122 | Ep: pct application non-entry in european phase |